Summary | Bottom line: WuXi PharmaTech's privatization will be
followed by at least 3-4 more similar buy-outs this year for
US-traded Chinese stocks, including a 50-50 chance that Renren
will attempt a privatization by mid-year. I'm beginning to feel
like I should start a betting list of Chinese candidates that
may de-list from New York, following word ...
followed by at least 3-4 more similar buy-outs this year for
US-traded Chinese stocks, including a 50-50 chance that Renren
will attempt a privatization by mid-year. I'm beginning to feel
like I should start a betting list of Chinese candidates that
may de-list from New York, following word ...
youngchinabiz.com | 11 November 2015